These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38953731)

  • 1. The potential significance of hepcidin evaluation in progressive supranuclear palsy.
    Alster P; Otto-Ślusarczyk D; Wiercińska-Drapało A; Struga M; Madetko-Alster N
    Brain Behav; 2024 Jun; 14(6):e3552. PubMed ID: 38953731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of glial cell line-derived neurotrophic factor analysis in Progressive Supranuclear Palsy.
    Alster P; Otto-Ślusarczyk D; Szlufik S; Duszyńska-Wąs K; Drzewińska A; Wiercińska-Drapało A; Struga M; Kutyłowski M; Friedman A; Madetko-Alster N
    Sci Rep; 2024 Feb; 14(1):2805. PubMed ID: 38307947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease.
    Pellicano C; Assogna F; Cellupica N; Piras F; Pierantozzi M; Stefani A; Cerroni R; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Parkinsonism Relat Disord; 2017 Dec; 45():50-56. PubMed ID: 29037499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism.
    Assogna F; Pellicano C; Cravello L; Savini C; Macchiusi L; Pierantozzi M; Stefani A; Mercuri B; Caltagirone C; Pontieri FE; Spalletta G
    Brain Behav; 2019 Dec; 9(12):e01448. PubMed ID: 31743601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
    Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
    Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant.
    Gatto RG; Martin PR; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Dickson DW; Josephs KA; Whitwell JL
    Neuroimage Clin; 2022; 35():103030. PubMed ID: 35597031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy.
    Seki M; Seppi K; Mueller C; Potrusil T; Goebel G; Reiter E; Nocker M; Steiger R; Wildauer M; Gizewski ER; Wenning GK; Poewe W; Scherfler C
    Parkinsonism Relat Disord; 2018 Apr; 49():81-87. PubMed ID: 29463454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.
    Quattrone A; Morelli M; Nigro S; Quattrone A; Vescio B; Arabia G; Nicoletti G; Nisticò R; Salsone M; Novellino F; Barbagallo G; Le Piane E; Pugliese P; Bosco D; Vaccaro MG; Chiriaco C; Sabatini U; Vescio V; Stanà C; Rocca F; Gullà D; Caracciolo M
    Parkinsonism Relat Disord; 2018 Sep; 54():3-8. PubMed ID: 30068492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Track density imaging: A reliable method to assess white matter changes in Progressive Supranuclear Palsy with predominant parkinsonism.
    Nigro S; Barbagallo G; Bianco MG; Morelli M; Arabia G; Quattrone A; Gasparini S; Cascini GL; Quattrone A
    Parkinsonism Relat Disord; 2019 Dec; 69():23-29. PubMed ID: 31665684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson's disease.
    Sitek EJ; Wieczorek D; Konkel A; Dąbrowska M; Sławek J
    Psychiatr Pol; 2017 Aug; 51(4):647-659. PubMed ID: 28987055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive supranuclear palsy.
    Giagkou N; Höglinger GU; Stamelou M
    Int Rev Neurobiol; 2019; 149():49-86. PubMed ID: 31779824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and diagnostic potential of R
    Beliveau V; Müller C; Steiger R; Gizewski ER; Poewe W; Seppi K; Scherfler C
    Parkinsonism Relat Disord; 2022 Aug; 101():43-48. PubMed ID: 35792337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome.
    Picillo M; Tepedino MF; Abate F; Ponticorvo S; Erro R; Cuoco S; Oksuz N; Di Salle G; Di Salle F; Esposito F; Pellecchia MT; Manara R; Barone P
    Neurol Sci; 2022 Jun; 43(6):3677-3682. PubMed ID: 35106692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism.
    Srulijes K; Reimold M; Liscic RM; Bauer S; Dietzel E; Liepelt-Scarfone I; Berg D; Maetzler W
    Mov Disord; 2012 Jan; 27(1):151-5. PubMed ID: 22359740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy.
    Lin WY; Lin KJ; Weng YH; Yen TC; Shen LH; Liao MH; Lu CS
    Nucl Med Commun; 2010 Nov; 31(11):974-80. PubMed ID: 20717064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.